We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

GRIFOLS DIAGNOSTIC

Bioscience division carries out all activities relating to plasma products for therapeutic use, including research, d... read more Featured Products: More products

Download Mobile App




Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels

By LabMedica International staff writers
Posted on 09 Apr 2025

Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership with IBL International GmbH (Hamburg, Germany), a Tecan company and a leader in specialty diagnostics. More...

Together the two companies aim to change the clinical diagnostics landscape. Their collaboration will provide clinical laboratories with Grifols’ highly sensitive multiplexing instrumentation running IBL’s assays customized exclusively for the Grifols platform. Maximum precision, sensitivity and operational efficiency come from Grifols’ proprietary application of single molecule counting (SMC) technology, as well as full automation and random-access, which allows high sample throughput by enabling the application of individual analyte and assay types without any specific order. The combination of ultra-high sensitivity and multiplexing opens unique opportunities for clinical laboratories.

Initially the Grifols-IBL partnership will focus on biomarker panels for neurological and oncological conditions among others. Ultra-sensitive Grifols technology can detect signals of disease in the early stages, potentially raising the efficacy of disease-modifying interventions. Multiplexed panels will improve lab operations and can be more precise in case of multivariate biomarkers. Grifols, already a global leader in transfusion medicine, has in recent years expanded into the larger clinical diagnostic space, both through strategic partnerships and innovative testing technology.

The company’s clinical diagnostic portfolio includes the Promonitor family of assays, which measure biological drug and anti-drug antibody levels in patients receiving treatment for chronic inflammatory diseases and other indications. The portfolio also includes the AlphaID test, designed to detect the most prevalent variants associated with alpha-1 antitrypsin deficiency, also known as genetic chronic obstructive pulmonary disorder, a serious respiratory ailment. In 2023 Grifols launched its AlphaID At Home service, enabling U.S. adults to screen for the genetic risk of alpha-1 antitrypsin deficiency without prescription from a healthcare professional. Since then, approximately 75,000 tests have been ordered. Grifols’ expanding specialized diagnostics solutions also include a comprehensive range of products to help standardize the diagnosis of autoimmune diseases as well as hardware and assay solutions for autoimmune and infectious disease testing. The agreement with IBL includes a framework for product development, manufacturing and commercialization to ensure reliable and efficient delivery of these new solutions to the market.

“Our revolutionary platform combining multiplexing and ultrasensitive single molecule counting technology is unique for in-vitro diagnostics, demonstrating our growing capabilities and expertise in the expanding clinical diagnostics market,” said Antonio Martinez, President Grifols Diagnostic Business Unit. “We are excited to partner with IBL as their solid expertise in specialty diagnostic assay development is vital to be able to provide laboratorians with the solutions they need.”

“Partnering with a leader like Grifols allows us to scale healthcare innovation globally,” said Mukta Acharya, Head of Tecan’s Life Sciences business division. “By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in specialty diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.”


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Clostridium Difficile Test
Immunocard Toxins A&B
New
PSA Test
Humasis PSA Card
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.